马应龙(600993) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter reached ¥864,101,704.84, representing a year-on-year increase of 7.22%[2] - Net profit attributable to shareholders was ¥145,592,209.22, reflecting a year-on-year growth of 6.26%[2] - The net profit after deducting non-recurring gains and losses was ¥140,415,128.49, with a year-on-year increase of 2.35%[2] - Total operating revenue for the first three quarters of 2024 reached CNY 2,791,816,831.37, an increase of 14.1% compared to CNY 2,446,244,490.16 in the same period of 2023[13] - Net profit attributable to shareholders of the parent company for the first three quarters of 2024 was CNY 457,504,222.25, up from CNY 418,381,342.81 in the previous year, reflecting a growth of 9.4%[14] - The net profit for the first three quarters of 2024 was CNY 463,231,519.36, up 6.3% from CNY 435,579,725.13 in the previous year[21] - The total comprehensive income for the first three quarters of 2024 was CNY 463,231,519.36, compared to CNY 435,579,725.13 in the previous year[21] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥5,124,759,268.86, an increase of 6.11% compared to the end of the previous year[3] - The company's total assets reached CNY 5,124,759,268.86 at the end of the third quarter of 2024, compared to CNY 4,829,523,622.47 in the same period of 2023, indicating a growth of 6.1%[12] - The total assets as of September 30, 2024, amounted to CNY 5,268,216,867.06, compared to CNY 4,415,931,097.09 at the end of 2023, reflecting an increase of 19.3%[17] - The company's total liabilities as of the end of the third quarter of 2024 were CNY 994,307,397.57, compared to CNY 959,617,984.37 at the end of the third quarter of 2023, showing an increase of 3.6%[12] - The total liabilities increased to CNY 1,078,284,253.17 as of September 30, 2024, compared to CNY 516,808,446.18 at the end of 2023, representing a rise of 108.5%[18] Shareholder Information - Shareholders' equity attributable to the parent company was ¥4,000,705,971.94, up by 7.03% from the previous year[3] - The total equity attributable to shareholders of the parent company was CNY 4,000,705,971.94, up from CNY 3,737,968,219.51 in the previous year, marking an increase of 7.0%[12] - The total number of ordinary shareholders at the end of the reporting period was 34,027[7] Cash Flow - The net cash flow from operating activities increased significantly by 314.97% year-to-date, primarily due to growth in pharmaceutical industrial and commercial revenue[6] - In the first three quarters of 2024, the cash inflow from operating activities reached CNY 2,754,937,729.63, an increase of 19.4% compared to CNY 2,304,679,265.39 in the same period of 2023[15] - The net cash flow from operating activities was CNY 317,286,449.82, significantly up from CNY 76,460,034.32 in the previous year, marking a growth of 315.5%[15] - The company's cash flow from operating activities generated a net amount of CNY 657,858,596.32, down from CNY 816,689,177.53 in the same period last year[22] Expenses - The total operating costs for the first three quarters of 2024 amounted to CNY 2,212,469,157.11, representing an increase of 10.4% from CNY 2,004,757,828.14 in the same period of 2023[13] - Research and development expenses for the first three quarters of 2024 were CNY 51,039,415.65, compared to CNY 48,389,153.88 in 2023, indicating a rise of 3.4%[13] - Research and development expenses for the first three quarters of 2024 were CNY 43,121,388.43, slightly up from CNY 39,492,365.12 in 2023[20] - The financial expenses for the first three quarters of 2024 showed a significant decrease, with interest expenses at CNY 4,021,280.55 compared to CNY 13,742,725.58 in the previous year, a reduction of 70.7%[13] Investments - The company reported a decrease in investment income to CNY 17,523,676.86 from CNY 65,621,956.61 in the previous year[20] - The company has ongoing development expenditures of approximately RMB 97.44 million, up from RMB 71.66 million, indicating a growth of about 36.06%[11] - The long-term equity investments as of September 30, 2024, were CNY 1,198,980,445.08, up from CNY 1,172,206,665.34 at the end of 2023, indicating a growth of 2.3%[17] Inventory and Receivables - Accounts receivable rose to approximately RMB 310.54 million, compared to RMB 246.37 million, marking an increase of approximately 25.99%[10] - Inventory increased to approximately RMB 316.06 million from RMB 273.48 million, representing a growth of about 15.57%[10] - The company's inventory increased to CNY 120,957,487.61 from CNY 98,129,648.81, showing a growth of 23.2%[17]